Business
RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
RenovoRx Joins the Ranks of Google, Nvidia, Adidas, Walmart, and MoreMOUNTAIN VIEW, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that it has been named on Fast Company’s prestigious list of the World’s Most Innovative Companies of 2026 as number 10 in the medical device c
About this update from Renovorx, Inc.
[{"type":"image","alt":"RenovoRx, Inc.","displaySize":"","headline":null,"caption":"RenovoRx, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":47,"url":"https://media.zenfs.com/en/globenewswire.com/ab41ac143cad3cd5a5d7e95f545a721c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KH8PPWGWgkhj4V41vXuuLA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY2/https://media.zenfs.com/en/globenewswire.com/ab41ac143cad3cd5a5d7e95f545a721c","width":300,"height":47}},"lazy":false},{"type":"text","content":"RenovoRx Joins the Ranks of Google, Nvidia, Adidas, Walmart, and More","length":69,"tagName":"p"},{"type":"text","content":"MOUNTAIN VIEW, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that it has been named on Fast Company’s prestigious list of the World’s Most Innovative Companies of 2026 as number 10 in the medical device category. This annual recognition highlights organizations that are shaping industry and culture through their innovations.","length":553,"tagName":"p"},{"type":"text","content":"“We’re honored to be named one of the 2026 World’s Most Innovative Medical Device Companies by Fast Company,” said Shaun Bagai, Chief Executive Officer of RenovoRx. “This recognition reflects our team's commitment to transforming the lives of cancer patients through innovative solutions for targeted delivery of therapeutic agents in difficult-to-treat tumors, like pancreatic cancer.”","length":390,"tagName":"p"},{"type":"text","content":"RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, enabled by the RenovoCath device, is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy. The Company’s mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of therapeutic agents.","length":604,"tagName":"p"},{"type":"text","content":"Recently, RenovoRx achiev...